Development and Economic Evaluation of a Patient-Centered Care Model for Children With Duchenne Muscular Dystrophy: Protocol for a Quasi-Experimental Study.
Duchenne muscular dystrophy
caregiver
caregivers
cost of illness
disabilities
disability
effective
intervention
patient-centered care
pediatrics
policy
psychological
quality of life
treatment
Journal
JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504
Informations de publication
Date de publication:
28 Apr 2023
28 Apr 2023
Historique:
received:
08
09
2022
accepted:
30
01
2023
revised:
30
01
2023
medline:
28
4
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
epublish
Résumé
Duchenne muscular dystrophy (DMD) is a rare progressive muscular disease that primarily affects boys. A lack of comprehensive care for patients living with DMD is directly associated with a compromised quality of life (QoL) for those affected and their caregivers. This disease also has a huge economic impact on families as its treatment requires substantial direct, indirect, and informal care costs. This study presents a protocol developed to evaluate the feasibility and efficacy of a patient-centered care (PCC) model for children with DMD. The care model was designed with the aim to empower families, improve QoL, and reduce economic burden on their families. This study is planned as a quasi-experimental study that will enroll 70 consecutive families with boys (aged 5-15 years) with DMD visiting a tertiary care center. The study is being conducted in 2 phases (preintervention and postintervention phases, referred to as phase 1 and phase 2, respectively). During phase 1, the patients received routine care. The study is now in phase 2, with the intervention currently being administered. The intervention is based on the PCC model individualized by the intervention team. The model has a comprehensive DMD telecare component that includes teleconsultation as one of its key components to reduce in-person physician visits at the health facility. Teleconsultation is especially beneficial for late-ambulatory and nonambulatory patients. Data on economic burden are being collected for out-of-pocket expenses for both phases during in-person visits via telephone or messaging apps on a monthly basis. QoL data for patients and their primary caregivers are being collected at 3 time points (ie, time of enrollment, end of phase 1, and end of phase 2). Outcome measures are being assessed as changes in economic burden on families and changes in QoL scores. Participant recruitment began in July 2021. The study is ongoing and expected to be completed by March 2023. The findings based on baseline data are expected to be submitted for publication in 2023. This paper outlines a research proposal developed to study the impact of a PCC model for patients with DMD in low- and middle-income countries (LMICs). This study is expected to provide evidence of whether a multicomponent, patient-centric intervention could reduce economic burdens on families and improve their QoL. The results of this study could guide policy makers and health professionals in India and other LMICs to facilitate a comprehensive care program for patients living with DMD. The economic impact of a rare disease is an important consideration to formulate or evaluate any health policy or intervention related to new treatments and financial support schemes. Clinical Trials Registry India (ICMR-NIMS) CTRI/2021/06/034274; https://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=56650. PRR1-10.2196/42491.
Sections du résumé
BACKGROUND
BACKGROUND
Duchenne muscular dystrophy (DMD) is a rare progressive muscular disease that primarily affects boys. A lack of comprehensive care for patients living with DMD is directly associated with a compromised quality of life (QoL) for those affected and their caregivers. This disease also has a huge economic impact on families as its treatment requires substantial direct, indirect, and informal care costs.
OBJECTIVE
OBJECTIVE
This study presents a protocol developed to evaluate the feasibility and efficacy of a patient-centered care (PCC) model for children with DMD. The care model was designed with the aim to empower families, improve QoL, and reduce economic burden on their families.
METHODS
METHODS
This study is planned as a quasi-experimental study that will enroll 70 consecutive families with boys (aged 5-15 years) with DMD visiting a tertiary care center. The study is being conducted in 2 phases (preintervention and postintervention phases, referred to as phase 1 and phase 2, respectively). During phase 1, the patients received routine care. The study is now in phase 2, with the intervention currently being administered. The intervention is based on the PCC model individualized by the intervention team. The model has a comprehensive DMD telecare component that includes teleconsultation as one of its key components to reduce in-person physician visits at the health facility. Teleconsultation is especially beneficial for late-ambulatory and nonambulatory patients. Data on economic burden are being collected for out-of-pocket expenses for both phases during in-person visits via telephone or messaging apps on a monthly basis. QoL data for patients and their primary caregivers are being collected at 3 time points (ie, time of enrollment, end of phase 1, and end of phase 2). Outcome measures are being assessed as changes in economic burden on families and changes in QoL scores.
RESULTS
RESULTS
Participant recruitment began in July 2021. The study is ongoing and expected to be completed by March 2023. The findings based on baseline data are expected to be submitted for publication in 2023.
CONCLUSIONS
CONCLUSIONS
This paper outlines a research proposal developed to study the impact of a PCC model for patients with DMD in low- and middle-income countries (LMICs). This study is expected to provide evidence of whether a multicomponent, patient-centric intervention could reduce economic burdens on families and improve their QoL. The results of this study could guide policy makers and health professionals in India and other LMICs to facilitate a comprehensive care program for patients living with DMD. The economic impact of a rare disease is an important consideration to formulate or evaluate any health policy or intervention related to new treatments and financial support schemes.
TRIAL REGISTRATION
BACKGROUND
Clinical Trials Registry India (ICMR-NIMS) CTRI/2021/06/034274; https://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=56650.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)
UNASSIGNED
PRR1-10.2196/42491.
Identifiants
pubmed: 37115592
pii: v12i1e42491
doi: 10.2196/42491
pmc: PMC10182458
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e42491Informations de copyright
©Titiksha Sirari, Renu Suthar, Amarjeet Singh, Shankar Prinja, Vishwas Gupta, Manisha Malviya, Akashdeep Singh Chauhan, Naveen Sankhyan. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 28.04.2023.
Références
Indian J Nephrol. 2008 Oct;18(4):141-9
pubmed: 20142925
Health Aff (Millwood). 2013 Feb;32(2):207-14
pubmed: 23381511
Value Health. 2017 Mar;20(3):466-473
pubmed: 28292492
Lancet. 2018 Feb 3;391(10119):451-461
pubmed: 29174484
Medicina (Kaunas). 2020 Aug 24;56(9):
pubmed: 32846887
BMJ Open. 2020 Nov 20;10(11):e039517
pubmed: 33444194
PLoS One. 2011;6(6):e20821
pubmed: 21695127
Arq Neuropsiquiatr. 2015 Jan;73(1):52-7
pubmed: 25608128
Health Aff (Millwood). 2013 Feb;32(2):216-22
pubmed: 23381513
PLoS Med. 2011 Sep;8(9):e1001087
pubmed: 21909246
Orphanet J Rare Dis. 2017 Apr 26;12(1):79
pubmed: 28446219
Neurology. 2014 Aug 5;83(6):529-36
pubmed: 24991029
Med J Aust. 2003 Sep 1;179(5):253-6
pubmed: 12924973
Orphanet J Rare Dis. 2017 Aug 18;12(1):141
pubmed: 28821278
Lancet Neurol. 2018 Mar;17(3):251-267
pubmed: 29395989
Neurodegener Dis Manag. 2019 Jun;9(3):123-133
pubmed: 31166138
Inj Prev. 2000 Sep;6(3):177-9
pubmed: 11003181
Lancet Neurol. 2010 Jan;9(1):77-93
pubmed: 19945913
J R Soc Med. 2013 Oct;106(10):399-407
pubmed: 23759884
Vasc Med. 2008 Aug;13(3):251-3
pubmed: 18687763
Malays Fam Physician. 2008 Apr 30;3(1):7-13
pubmed: 25606105
Cochrane Database Syst Rev. 2016 May 05;(5):CD003725
pubmed: 27149418
Indian J Pediatr. 2018 Apr;85(4):276-281
pubmed: 28653137
Neurol India. 2018 Jan-Feb;66(1):77-82
pubmed: 29322964
Health Educ Behav. 2016 Feb;43(1):25-34
pubmed: 25845376
Lancet Neurol. 2018 Apr;17(4):347-361
pubmed: 29395990
Neurology. 2016 Jul 26;87(4):401-9
pubmed: 27343068
J Clin Epidemiol. 2017 Sep;89:188-198
pubmed: 28676426
Disabil Rehabil. 2017 Jul;39(14):1408-1413
pubmed: 27347814
Int J Environ Res Public Health. 2016 Jul 02;13(7):
pubmed: 27384572
Dev Med Child Neurol. 2017 Nov;59(11):1152-1157
pubmed: 28963725
Health Qual Life Outcomes. 2018 Dec 19;16(1):237
pubmed: 30567556
J Pediatr Endocrinol Metab. 2021 Apr 12;34(5):573-581
pubmed: 33838091
Muscle Nerve. 1983 Feb;6(2):91-103
pubmed: 6343858
Brain Dev. 2020 Mar;42(3):277-288
pubmed: 31980267
J Pediatr. 2017 Mar;182:296-303.e1
pubmed: 28043681
Clinicoecon Outcomes Res. 2013 Nov 18;5:565-73
pubmed: 24273412
Pharmacoecon Open. 2018 Jun;2(2):179-190
pubmed: 29623618
Health Qual Life Outcomes. 2012 May 22;10:43
pubmed: 22545870
J Child Neurol. 2021 Mar;36(3):177-185
pubmed: 33034535